On May 28, 2021, Timothy Daly, Executive Vice President, Finance, Corporate Controller and Treasurer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective June 22, 2021. Mr. Daly did not resign as a result of a disagreement with the Company on any matter relating to the Company’s operations, policies or practices, including its controls or financial-related matters. On June 2, 2021, the Board of Directors of the Company (the “Board”) appointed Jeffrey Rona, the Company’s then-current Chief Business Officer, to serve as the Company’s Chief Business and Financial Officer, effective as of June 2, 2021. The Board also appointed Mr. Rona to serve as the Company’s Principal Financial Officer and Principal Accounting Officer, and accordingly removed Mr. Daly from such roles, effective as of June 2, 2021. Mr. Rona’s biography and business experience is included in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 30, 2021, and such information is incorporated herein by reference.